May 13th 2024
While urologists and oncologists agreed on many barriers and facilitators of first-line treatment intensification for metastatic castrate-sensitive prostate cancer, there were also a number of differing beliefs, including whether there is enough clinical support.
Cost of Care for Malignant and Benign Renal Masses
Methods for better identifying malignant versus benign disease before nephrectomy could provide significant benefits to patients and payers.
Read More
Health Reform Will Cost Cancer Patients
August 8th 2013In an effort to offset cost increases associated with the Affordable Care Act (ACA), the Obama administration intends to expand hospitals' access of the 340B discount drug plan. While the expansion may sound promising to some, many others worry that the program will threaten the quality of care, as increased participation risks higher potential for abuse. Even worse, the 340B program will likely rise the cost of cancer care.
Read More
Narrowing Physician Access Puts Pharma in a Bind
August 1st 2013Oncologists have a reputation to maintain - and according to the latest report from ZS Associates, when it comes to fortifying against pharmaceutical sales representatives, the specialty remains characteristically hardboiled for the second year in a row.
Read More
Segment 5- New Payment Models in Oncology
July 29th 2013It's very, very complex to try to envision how you would come up with a single payment for an episode and not have a thousand different types of episodes in order to capture the heterogeneity of these diseases and the cost, said Dr Malin when asked to discuss the bundled payment method in oncology.
Read More
Segment 2- Emerging Immunotherapies for the Treatment of Metastatic Melanoma
July 29th 2013Dr Ribas opened this segment by discussing the new immunotherapy agents used in the treatment of metastatic melanoma. Specifically, he discussed the agents vemurafenib (Zelboraf), dabrafenib (Taflinar), and trametinib (Mekinist).
Read More
Segment 1- Introduction and Therapeutic Overview
July 29th 2013Panel moderator and AJMC co-editor-in-chief Dr Mark Fendrick introduced panelists Jennifer Malin, MD, PhD, manager and medical director of oncology, WellPoint; Jeffrey Weber, MD, PhD, senior member, H. Lee Moffitt Cancer Center Director, Donald A. Adam Comprehensive Melanoma Research Center; and Antoni Ribas, MD, PhD, Jonsson Comprehensive Cancer Center, UCLA.
Read More
More Evidence Not All Prostate Cancers Need Treatment
July 22nd 2013In a study of older men who had died from causes other than prostate cancer, almost half were found to have prostate tumors. And up to half of those tumors detected on autopsy would have qualified for treatment had doctors known about them while the men lived, though none had been the cause of death.
Read More
Segment 5: The Role of Companion Diagnostics/The Effect of New Payment Models
July 18th 2013In the final segment, panelists examine the use of companion diagnostics to determine proper patient utilization. Dr. Chernew asks if the required diagnostic testing is being appropriately used and if they are being covered by payers.
Read More
Segment 4: Reimbursement and Clinical Pathways
July 18th 2013This segment of the panel discussion takes a closer look at the episode of cost for a patient going to a hospital versus a private office setting. Panelists agree that the cost of hospital care is not that much greater than in the office.
Read More
Segment 3: How Payers are assessing the Value of New Agents
July 18th 2013Dr. Chernew asks the panelists how payers address the value of these costly combination therapies when there are less expensive options available. Dr. Newcomer says that the drugs being discussed are, in fact, having a significant clinical effect.
Read More
Segment 1: Introduction and Patient Population
July 18th 2013Moderator and AJMC co-editor-in-chief, Dr. Michael Chernew delivers a brief overview of the discussion. The discussion focuses on the use of trastuzumab emtansine (Kadcyla) and pertuzumab (Perjeta). Panelists address the patient populations for the two agents and identify which are eligible to take the targeted therapy.
Read More